Transcatheter mitral valve repair improves outcomes in patients with heart failure and moderate-to-severe or severe secondary mitral regurgitation compared with medical therapy alone, according to data from the COAPT trial, presented at the 2018 TCT conference. A total of 614 patients were randomly assigned to receive a MitraClip device (Abbott) plus medical therapy or medical therapy alone. During 24 months of follow-up, the rate of the primary end point (hospitalizations for heart failure) was 35.8% per patient-year in the device group versus 67.9% per patient-year in the control group (HR 0.53, 95% CI 0.40–0.70, P < 0.001). The rate of the primary safety end point (freedom from device-related complication at 12 months) in the device group was 96.6%, which exceeded the prespecified objective performance goal of 88.0% (P < 0.001). All-cause mortality within 24 months was 29.1% and 46.1% in each group, respectively (HR 0.62, 95% CI 0.46–0.82, P < 0.001).
References
Original article
Stone, G. W. et al. Transcatheter mitral-valve repair in patients with heart failure. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1806640 (2018)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lim, G.B. Benefit of the MitraClip for mitral regurgitation. Nat Rev Cardiol 15, 728 (2018). https://doi.org/10.1038/s41569-018-0111-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41569-018-0111-z